• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
GLP-1 Receptor Agonists in Orthopaedic Surgery: Implications for Perioperative Care and Outcomes: An Orthopaedic Surgeon's Perspective.骨科手术中的胰高血糖素样肽-1受体激动剂:对围手术期护理和结果的影响:骨科医生的观点
J Bone Joint Surg Am. 2025 Jul 10;107(16):1879-1886. doi: 10.2106/JBJS.24.01287.
2
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.用于慢性肾病和糖尿病患者的胰高血糖素样肽1(GLP-1)受体激动剂。
Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.
3
Effects of preoperative glucagon-like peptide-1 receptor agonist therapy on weight loss following bariatric surgery.术前胰高血糖素样肽-1受体激动剂治疗对减肥手术后体重减轻的影响。
Surg Endosc. 2025 Jun 9. doi: 10.1007/s00464-025-11838-7.
4
Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.胰高血糖素样肽 1 受体激动剂与 2 型糖尿病患者的 13 种肥胖相关癌症。
JAMA Netw Open. 2024 Jul 1;7(7):e2421305. doi: 10.1001/jamanetworkopen.2024.21305.
5
Transforming Care: Implications of Glucagon Like Peptide-1 Receptor Agonists on Physical Therapist Practice.变革护理:胰高血糖素样肽-1受体激动剂对物理治疗师实践的影响
Phys Ther. 2025 Jun 2;105(6). doi: 10.1093/ptj/pzaf061.
6
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.七种胰高血糖素样肽-1 受体激动剂和多激动剂在肥胖或超重患者中的减肥作用:一项更新的随机对照试验的系统评价和网络荟萃分析。
Metabolism. 2024 Dec;161:156038. doi: 10.1016/j.metabol.2024.156038. Epub 2024 Sep 19.
7
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂(GLP-1 RAs)减肥效果的网状Meta分析的数量、质量及结果:一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
8
Effect of glucagon-like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta-analysis.胰高血糖素样肽1受体激动剂对肥胖患者收缩压的影响:有无糖尿病患者的系统评价和网状荟萃分析
Clin Obes. 2025 Aug;15(4):e70012. doi: 10.1111/cob.70012. Epub 2025 Apr 23.
9
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.钠-葡萄糖共转运蛋白 2(SGLT-2)抑制剂和胰高血糖素样肽-1(GLP-1)受体激动剂治疗 2 型糖尿病:随机对照试验的系统评价和网络荟萃分析。
BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573.
10
Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials.胰高血糖素样肽-1受体激动剂与中风:心血管结局试验的系统评价和荟萃分析
Int J Stroke. 2024 Oct;19(8):876-887. doi: 10.1177/17474930241253988. Epub 2024 May 21.

本文引用的文献

1
Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period.围手术期安全使用胰高血糖素样肽-1受体激动剂的多学会临床实践指南。
Clin Gastroenterol Hepatol. 2024 Oct 29. doi: 10.1016/j.cgh.2024.10.003.
2
Does use of glucagon-like peptide-1 agonists increase perioperative complications in patients undergoing shoulder arthroplasty?使用胰高血糖素样肽-1激动剂会增加接受肩关节置换术患者的围手术期并发症吗?
J Shoulder Elbow Surg. 2025 Apr;34(4):997-1006. doi: 10.1016/j.jse.2024.07.045. Epub 2024 Sep 23.
3
Glucagon-Like Peptide Receptor-1 Agonists Used for Medically-Supervised Weight Loss in Patients With Hip and Knee Osteoarthritis: Critical Considerations for the Arthroplasty Surgeon.用于髋膝关节骨关节炎患者医学监督下减肥的胰高血糖素样肽受体-1激动剂:关节置换外科医生的关键考量
Arthroplast Today. 2024 Jun 27;27:101327. doi: 10.1016/j.artd.2024.101327. eCollection 2024 Jun.
4
No Difference in Short-term Surgical Outcomes From Semaglutide Treatment for Type 2 Diabetes Mellitus After Cervical Decompression and Fusion: A Propensity Score-matched Analysis.司美格鲁肽治疗2型糖尿病患者颈椎减压融合术后短期手术结局无差异:一项倾向评分匹配分析
Spine (Phila Pa 1976). 2025 Apr 15;50(8):515-521. doi: 10.1097/BRS.0000000000005099. Epub 2024 Jul 22.
5
Pharmacotherapy of Weight-loss and Obesity with a Focus on GLP 1-Receptor Agonists.以胰高血糖素样肽-1受体激动剂为重点的减肥与肥胖症药物治疗
J Clin Pharmacol. 2024 Oct;64(10):1204-1221. doi: 10.1002/jcph.2487. Epub 2024 Jun 26.
6
The Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists.GLP-1 受体激动剂治疗患者的骨关节炎进展和全关节置换术的五年发生率。
J Arthroplasty. 2024 Oct;39(10):2433-2439.e1. doi: 10.1016/j.arth.2024.06.008. Epub 2024 Jun 8.
7
Risk of rotator cuff tear and rotator cuff repair surgery comparison between sodium-glucose cotransporter 2 inhibitors and glucagon like peptide-1 receptor agonists: A real-world study.钠-葡萄糖共转运蛋白 2 抑制剂与胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病患者发生肩袖撕裂及肩袖修复手术风险的比较:一项真实世界研究。
Diabetes Metab. 2024 Mar;50(2):101522. doi: 10.1016/j.diabet.2024.101522. Epub 2024 Feb 8.
8
The benefits of GLP1 receptors in cardiovascular diseases.胰高血糖素样肽-1受体在心血管疾病中的益处。
Front Clin Diabetes Healthc. 2023 Dec 8;4:1293926. doi: 10.3389/fcdhc.2023.1293926. eCollection 2023.
9
Semaglutide Use Prior to Total Hip Arthroplasty Results in Fewer Postoperative Prosthetic Joint Infections and Readmissions.全髋关节置换术前使用司美格鲁肽可减少术后人工关节感染和再入院情况。
J Arthroplasty. 2024 Mar;39(3):716-720. doi: 10.1016/j.arth.2023.12.023. Epub 2023 Dec 19.
10
The Impact of Glucagon-Like Peptide-1 Agonists on Hip and Knee Arthroplasty and Perioperative Considerations.胰高血糖素样肽-1 类似物对髋关节和膝关节置换术的影响及围手术期注意事项。
J Arthroplasty. 2024 Jun;39(6):1455-1458. doi: 10.1016/j.arth.2023.12.002. Epub 2023 Dec 8.

骨科手术中的胰高血糖素样肽-1受体激动剂:对围手术期护理和结果的影响:骨科医生的观点

GLP-1 Receptor Agonists in Orthopaedic Surgery: Implications for Perioperative Care and Outcomes: An Orthopaedic Surgeon's Perspective.

作者信息

Ramanathan Rahul, Lee Joon Y, Dalton Jonathan F, Lin Ryan T, Lee Isaac, Gonzalez Christopher, Shaw Jeremy D, Schroeder Gregory D, Kepler Christopher K, Spitnale Michael, Vaccaro Alexander R, Gabrielli Alexandra S, Wawrose Richard A

机构信息

Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.

The Orland Bethel Family MSK Research Center (BMRC), Pittsburgh, Pennsylvania.

出版信息

J Bone Joint Surg Am. 2025 Jul 10;107(16):1879-1886. doi: 10.2106/JBJS.24.01287.

DOI:10.2106/JBJS.24.01287
PMID:40833394
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12356572/
Abstract

➢ Glucagon-like peptide-1 (GLP-1) receptor agonists are a promising tool for preoperative weight loss in the patient who is undergoing orthopaedic surgery and has concomitant obesity and type-2 diabetes mellitus.➢ With regard to the perioperative management of GLP-1 receptor agonists for the orthopaedic surgeon, the American Society of Anesthesiologists (ASA) recommends withholding daily-dose GLP-1 therapy on the day of the elective surgical procedure and withholding weekly-dose therapy for the week prior to the procedure.➢ The ASA recommends postponing surgery or proceeding with "full stomach precautions" if the patient undergoing an orthopaedic procedure and taking GLP-1 therapy exhibits gastrointestinal symptoms on the day of the elective procedure.➢ In the trauma setting, patients taking GLP-1 therapy should proceed with the surgical procedure at the discretion of the surgeon with full stomach precautions or a preoperative point-of-care gastric ultrasound.➢ GLP-1 receptor agonists show the potential for disease modification in osteoarthritis and osteoporosis.

摘要

➢ 胰高血糖素样肽-1(GLP-1)受体激动剂是一种很有前景的工具,可用于接受骨科手术且伴有肥胖症和2型糖尿病的患者术前减重。

➢ 关于骨科医生对GLP-1受体激动剂的围手术期管理,美国麻醉医师协会(ASA)建议在择期手术当天停用每日剂量的GLP-1治疗,并在手术前一周停用每周剂量的治疗。

➢ ASA建议,如果接受骨科手术并正在接受GLP-1治疗的患者在择期手术当天出现胃肠道症状,则推迟手术或采取“饱胃预防措施”。

➢ 在创伤情况下,接受GLP-1治疗的患者应根据外科医生的判断进行手术,采取饱胃预防措施或术前即时胃超声检查。

➢ GLP-1受体激动剂在骨关节炎和骨质疏松症中显示出疾病改善的潜力。